Market Place
Sourcing Support
Evaxion Appeals Nasdaq Delisting, Remains Committed to Listing
13 Nov 2024 //
GLOBENEWSWIRE
Evaxion announces business update and Q3 2024 financial results
31 Oct 2024 //
GLOBENEWSWIRE
Evaxion to Update Business and Q3 2024 Financials on Oct. 31
28 Oct 2024 //
#N/A
Evaxion`s AI-Immunology Platform Validated In Clinical Trials
09 Oct 2024 //
GLOBENEWSWIRE
Evaxion`s AI-Immunology™ Platform Shows Better Prediction Power
03 Oct 2024 //
GLOBENEWSWIRE
Evaxion Expands Vaccine Development Collaboration With MSD
26 Sep 2024 //
GLOBENEWSWIRE
Merck bags options on Evaxion`s AI-designed vaccine candidates
26 Sep 2024 //
FIERCE BIOTECH
Evaxion Launches Improved AI-Immunology™ Platform For Vaccines
19 Sep 2024 //
GLOBENEWSWIRE
Evaxion Reports One-Year Data On AI Cancer Vaccine
16 Sep 2024 //
GLOBENEWSWIRE
Evaxion Obtains Proof-Of-Concept For Gonorrhea Vaccine
09 Sep 2024 //
GLOBENEWSWIRE
Evaxion Reports 69% Response Rate In Phase 2 Trial
09 Sep 2024 //
GLOBENEWSWIRE
Evaxion Announces Business Update and Second Quarter 2024 Financial Results
14 Aug 2024 //
GLOBENEWSWIRE
Evaxion To Announce Q2 2024 Results And Business Update On August 14
12 Aug 2024 //
GLOBENEWSWIRE
Evaxion To Present Clinical Data On Cancer Vaccine At ESMO Congress
08 Aug 2024 //
GLOBENEWSWIRE
Evaxion Presents Improved AI-Immunology At Computational Biology Event
16 Jul 2024 //
GLOBENEWSWIRE
Evaxion Reinforces Milestone Timeline and Provides Shareholder Update
03 Jul 2024 //
GLOBENEWSWIRE
Evaxion Receives Positive Feedback On Patent Application
26 Jun 2024 //
GLOBENEWSWIRE
Evaxion Publishes Data Showing 67% Response Rate For Cancer Vaccine EVX-01
17 Jun 2024 //
GLOBENEWSWIRE
Evaxion`s AI-Designed EVX-01 Shows Positive Immune Data In Phase 2
03 Jun 2024 //
GLOBENEWSWIRE
Evaxion Announces Business Update and First Quarter 2024 Financial Results
28 May 2024 //
GLOBENEWSWIRE
Evaxion Evx-01 Positive Phase 2: New Data At 2024 Asco Meeting
23 May 2024 //
GLOBENEWSWIRE
Evaxion Receives Nasdaq Notification
10 May 2024 //
GLOBENEWSWIRE
Evaxion & Undisclosed Collaborator Announce Encouraging Results for EVX-B1
02 Apr 2024 //
GLOBENEWSWIRE
Evaxion Announces Business Update and Full Year 2023 Financial Results
27 Mar 2024 //
GLOBENEWSWIRE
Evaxion Hosts R&D Day & Unveils the Broad Potential of Its AI-Immunology
19 Mar 2024 //
GLOBENEWSWIRE
Evaxion to Host R&D Day on March 19, 2024, Highlighting Technology Innovations
29 Feb 2024 //
GLOBENEWSWIRE
Evaxion Announces Completion of Initial Phases of Vaccine Collaboration with MSD
20 Feb 2024 //
GLOBENEWSWIRE
Evaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement
07 Feb 2024 //
GLOBENEWSWIRE
Evaxion Announces Closing of $15 Million Public Offering
06 Feb 2024 //
GLOBENEWSWIRE
Evaxion Biotech Announces Pricing of $15 Million Public Offering
01 Feb 2024 //
GLOBENEWSWIRE
Evaxion to Develop Tailored Novel Cancer Vaccines
24 Jan 2024 //
GLOBENEWSWIRE
Evaxion Announces Completion of ADS Ratio Change
22 Jan 2024 //
GLOBENEWSWIRE
Evaxion Announces Plan to Implement ADS Ratio Change
08 Jan 2024 //
GLOBENEWSWIRE
Evaxion Biotech Announces Closing of Private Placement
21 Dec 2023 //
GLOBENEWSWIRE
Evaxion Biotech Announces Private Placement Financing
19 Dec 2023 //
GLOBENEWSWIRE
Evaxion Announces Business Update and Third Quarter 2023 Financial Results
19 Dec 2023 //
GLOBENEWSWIRE
Evaxion to Unveil AI-Immunology Precision Cancer Vaccine Concept
28 Nov 2023 //
GLOBENEWSWIRE
Evaxion Presents Principle for AI Model Predicting Responses to Cancer Immunotherapy
15 Nov 2023 //
GLOBENEWSWIRE
Evaxion Shares Latest EVX-01 Phase 2 Clinical Data in Webinar
06 Nov 2023 //
GLOBENEWSWIRE
Evaxion Announces Encouraging Initial Phase 2 Clinical Data on EVX-01
31 Oct 2023 //
GLOBENEWSWIRE
New and Exciting Clinical Data on Evaxion™s AI-Immunology to be Presented
26 Oct 2023 //
GLOBENEWSWIRE
Evaxion Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
05 Oct 2023 //
GLOBENEWSWIRE
Evaxion Partners With Afrigen Biologics to Develop Novel mRNA Vaccine
20 Sep 2023 //
GLOBENEWSWIRE
Evaxion expands preclinical bacterial vaccine pipeline
18 Sep 2023 //
GLOBENEWSWIRE
Evaxion announces Executive Management Changes to strengthen the AI-strategy
29 Aug 2023 //
GLOBENEWSWIRE
Evaxion Announces Business Update and Second Quarter 2023 Financial Results
18 Aug 2023 //
GLOBENEWSWIRE
Evaxion announces financing commitments totaling up to USD 20M with Negma Group
01 Aug 2023 //
GLOBENEWSWIRE
Evaxion presents promising results on EVX-B1, an AI-designed vaccine
31 Jul 2023 //
GLOBENEWSWIRE
Evaxion AI technology identifies cancer vaccine targets associated with lsurvival of melanoma patients
03 Jun 2023 //
GLOBENEWSWIRE
Evaxion Announces Business Update and First Quarter 2023 Financial Results
31 May 2023 //
GLOBENEWSWIRE
Evaxion teases 67% response rate in PhI metastatic melanoma trial
26 May 2023 //
ENDPTS
Evaxion unveils proprietary genetic adjuvant technology
25 May 2023 //
GLOBENEWSWIRE
Evaxion announces Phase 1 data for its personalized cancer vaccine EVX-01
25 May 2023 //
GLOBENEWSWIRE
Evaxion to host R&D Day on May 25, 2023
16 May 2023 //
GLOBENEWSWIRE
Fourth quarter and full year 2022 financial results and business update
27 Apr 2023 //
GLOBENEWSWIRE
Evaxion announces promising clinical data for DNA immunotherapy EVX-02
18 Apr 2023 //
GLOBENEWSWIRE
Evaxion Announces Fast-Tracking of its New AI Discovery to Patients
28 Mar 2023 //
GLOBENEWSWIRE
Evaxion presents a new source of AI-derived immunotherapeutic targets
23 Mar 2023 //
GLOBENEWSWIRE
Evaxion to announce data for the personalized DNA cancer vaccine EVX-02
14 Mar 2023 //
GLOBENEWSWIRE
